

Comprehensive cardiovascular risk management – what does it mean in practice?

Leif Erhardt¹
Robert Moller²
Juan García Puig³

¹Department of Cardiology, University of Lund, Malmö University Hospital, Malmö, Sweden; ²Worldwide Medical Cardiovascular-Metabolic Endocrine Group, Pfizer Inc, New York, NY, USA; ³Metabolic and Vascular Risk Unit, Division of Internal Medicine, La Paz University Hospital, Madrid, Spain

Abstract: The continued movement away from the treatment of individual cardiovascular (CV) risk factors to managing overall and lifetime CV risk is likely to have a significant impact on slowing the rate of increase in cardiovascular disease (CVD). However, the management of CVD is currently far from optimal even in parts of the world with well-developed and well-funded healthcare systems. Effective implementation of the knowledge, treatment guidelines, diagnostic tools, therapeutic interventions, and management programs that exist for CVD continues to evade us. A thorough understanding of the multifactorial nature of CVD is essential to its effective management. Improvements continue to be made to management guidelines, risk assessment tools, treatments, and care programs pertaining to CVD. Ultimately, however, preventing the epidemic of CVD will require a combination of both medical and public health approaches. In addition to improvements in the “high-risk” strategy, which forms the basis of current CVD management, an increase in the utilization of population-based management strategies needs to be made to attempt to reduce the number of patients falling within the “at-risk” stratum for CVD. This review outlines how a comprehensive approach to CVD management might be achieved.

Keywords: cardiovascular disease, risk factors, high-risk strategies, public-health management, guidelines, implementation

Introduction

Cardiovascular disease (CVD) is one of the most prevalent and devastating health problems in the world and is responsible for approximately 30% of deaths worldwide (WHO 2005) which equates to about 16.6 million deaths (Figure 1). It is the leading cause of death in many developed countries and, by 2010, it is thought that CVD will be the leading cause of death in developing countries (WHO 2005). Furthermore, the mortality, financial, and medical resource costs of CVD worldwide are huge and increasing.

Efforts are being extended to investigate ways to optimally manage risk factors for CVD and to improve medical interventions for the disease. In some countries these efforts have been rewarded with reductions in CVD mortality, as seen in most Northern, Southern, and Western European countries (Rayner 2000). An example of a successful community-based intervention strategy was started in the North Karelia province of Finland in 1972 (Puska 1988; Vartiainen et al 1994; Puska et al 1998). The interventions aimed to change target risk factors and health behaviors (serum cholesterol, blood pressure, smoking, diet) at the population level. In the early 1970s middle-aged Finnish men had the highest mortality from CVD in the world, but since this prevention program was started the mortality rate decreased dramatically; from 1969–1971 to 1995 the age-standardized coronary heart disease (CHD) mortality (per 100,000) decreased in North Karelia by 73% (Puska et al 1998).

Correspondence: Leif Erhardt
University of Lund, Malmö University
Hospital, Altonagatan 5, S 211 38 Malmö,
Sweden
Tel +46 40 240750
Fax +46 40 240751
Email Leif.Erhardt@med.lu.se




Figure 1 The mortal and morbid consequences of cardiovascular disease.
Source: ^aWorld Health Organization, 2005

However, in many regions, reductions are not as impressive or conversely the prevalence of CVD is rising. Worldwide increases in CVD events are anticipated because the disease remains uncontrolled on a global scale. There is, therefore, a critical need to find ways to blunt the worldwide increase in CVD projected for forthcoming decades (Murray and Lopez 1997).

What may be surprising is that we already possess the knowledge and the tools to significantly reduce the burden of CVD risk. However, effectively implementing the treatment guidelines, diagnostic tools, therapeutic interventions, and management programs that exist for CVD somehow still manages to evade us. Among the reasons for this include the increasing number of people adopting lifestyles that are at odds with maintaining an acceptable CVD risk (WHO 2005; Chobanian et al 2003), elements of which may include poor diet, smoking, and physical inactivity. Furthermore, epidemics of conditions related to these unhealthy lifestyles (eg, diabetes and obesity) are escalating, which further increases the rise in CVD. For example, it has been estimated that there are more than 1 billion overweight adults and more than 300 million adults who are clinically obese (AHA 2003). Obesity rates have dramatically increased (>3 fold) in parts of North America, Eastern Europe, the Middle East, the Pacific Islands, Australia, and China since 1980 (AHA 2003).

The prevalence of diabetes (which is closely linked with obesity) is also increasing rapidly. For example, the worldwide prevalence of diabetes is expected to nearly double from 2.8% in 2000 to 4.4% in 2030, a rise from 171 million to 366 million people (Wild et al 2004). In the US, the prevalence of those diagnosed with diabetes has increased by 61% since 1990 (Rosamond et al 2007). It is estimated that 20.8 million Americans (7% of the population) now have diabetes (Rosamond et al 2007). Similarly, the prevalence of type 2 diabetes has now reached epidemic levels in Asia (Yoon et al 2006) with levels very similar to those in the US and Europe (approximately 7.8% in 2003). The highest rates in Europe are generally observed in countries of Central and Eastern Europe (International Diabetes Federation's Diabetes Atlas). The ever increasing worldwide burden of diabetes will have a substantial impact on the occurrence of CVD. The recent INTERHEART study revealed that worldwide those with diabetes are 2.37 times more likely to experience a myocardial infarction (MI) in comparison with those without diabetes (Yusuf et al 2004). Moreover, previous studies have demonstrated that diabetes is associated with a CV risk similar to that post-MI (Haffner et al 1998) and an equivalent risk to ageing 15 years (Booth et al 2006) (Table 1). Of note is the fact that diabetes has a far greater adverse impact on women, although women develop CHD at a later age, usually lagging behind men by about

Table 1 Major risk factors and protective factors for CVD

Category	Factor	Contribution to CVD
Modifiable risk factors	Hypertension	Continuous relationship between BP level and CVD risk above 135/85 mmHg
	Dyslipidemia	Elevated total cholesterol and LDL cholesterol, as well as low levels of HDL cholesterol, confer CVD risk
	Cigarette smoking	Risk of CHD is 2–4 times higher in smokers than in non-smokers. Risk starts with any daily amount and declines progressively after tobacco use is discontinued. Exposure to smoke also confers risk.
	Diabetes	Imposes a CV risk similar to myocardial infarction (Haffner et al 1998) and an equivalent risk to ageing 15 years (Booth et al 2006). Increases risk even when glucose levels are controlled
	Abdominal obesity	Major contributor to hypertension, dyslipidemia and diabetes mellitus. Male fat distribution associated with greater risk than female fat distribution
	Excess alcohol Sedentary lifestyle	Raises blood pressure, causes heart failure and can lead to stroke. Major contributor to hypertension, dyslipidemia and diabetes mellitus
Non-modifiable risk factors	Increasing age	Significantly increases risk of CVD in men >45 years and in women >55 years of age
	Male gender	Men have a higher risk of CVD than women of the same age and have heart attacks at an earlier age than women
	Family history of premature CVD	Increased risk in people with parents or siblings with history of CVD at a premature age (<55 years in male relative and <65 years in a female relative)
Protective factors	Daily consumption of fruit and vegetables	Lowers BP and increases HDL cholesterol levels
	Regular moderate alcohol consumption	Risk is lower in people who drink moderate amounts (average 1 drink/day for women and 2/day for men) than in non-drinkers
	Regular physical activity	Lowers BP and increases HDL cholesterol levels

Abbreviations: BP, blood pressure; CVD, cardiovascular disease; HDL, high density lipoprotein.

10 years (Lerner and Kannel 1986), women with diabetes are up to 50% more likely to die from CHD compared with men with diabetes (Natarajan et al 2003; Huxley et al 2006).

The management of CVD is currently in a state of transformation. In the past, the management process has centered on the modification of single risk factors, such as hypertension. However, there have been repeated calls to move away from this siloed approach (Ansell 2005; Giles et al 2005; Jackson et al 2005; Mancina 2006) and many treatment guidelines now recommend simultaneously adopting lifestyle and therapeutic interventions targeted at multiple risk factors (De Backer et al 2003; Joint British Societies 2005). This change of perception promises to have a positive impact on the success of treatment for the disease. This review aims to demonstrate how the consideration of the multifactorial nature of CVD needs to become the cornerstone of how CVD is viewed, assessed, and ultimately managed.

Key points

- CVD is responsible for approximately 30% of deaths worldwide.
- The multifactorial nature of CVD needs to underpin management strategies for the disease.
- To optimally manage CVD, therapeutic interventions need to target multiple risk factors.

Multifactorial nature of CVD

The numerous risk factors for CVD are usually categorized based on whether they are modifiable or are non-modifiable (Table 1). In addition, certain factors have been shown to be protective against the development of CVD, namely, daily consumption of fruit and vegetables, regular moderate alcohol consumption, and regular physical activity (McManus 2005). Evidence accumulated over the past 30 years has consistently demonstrated that these risk factors are linked epidemiologically, clinically, and metabolically (Neaton and Wentworth 1992; Asmar et al 2001; Thomas et al 2002; Felmeden et al 2003; Greenland et al 2003; Bhatt et al 2006).

One of the most revolutionary findings from epidemiological data is that hypertension usually occurs in conjunction with other major risk factors for CVD, namely, glucose intolerance, obesity, left ventricular hypertrophy, and dyslipidemia (Kannel 2000a, b; Asmar et al 2001; Greenland et al 2003; O'Meara et al 2004; Bhatt et al 2006).


This is thought to be because these factors are metabolically linked to hypertension, and could thus form a predisposition to development of the condition (Reaven et al 1996). Findings from various studies, including the Framingham Heart Study have shown that CVD risk factor “clustering” occurs frequently in individuals (Kannel 2000a, b; Asmar et al

2001; Greenland et al 2003; O'Meara et al 2004; Bhatt et al 2006). A cluster of 2 or more risk factors occurs in approximately half of hypertensive persons, a frequency twice that expected by chance (Kannel 2000a, b). Clusters of 3 or more risk factors occur at 4 times the expected rate (Kannel 2000a, b). In fact, only 10%–20% of cases of hypertension occur in the absence of other CVD risk factors (Kannel 2000a, b; Bhatt et al 2006), for example, in the Reduction of Atherothrombosis for Continued Health (REACH) registry, 90.3% of patients with hypertension had ≥ 3 risk factors (Figure 2) (Bhatt et al 2006). Furthermore, obesity and weight gain appear to be among the most important determinants of the rate of development of hypertension and the tendency for other risk factors to cluster with elevated blood pressure (BP) (Kannel 2000a).

Although much emphasis is placed on modifiable risk factors, it is important to appreciate the impact of non-modifiable risk factors such as gender and age, which may influence the potency of modifiable risk factors. Increasing age plays an important role in the risk equation. With each additional year of life comes an increased risk of CVD complications, and the prevalence of other risk factors such as hypertension (Vasan et al 2002) and dyslipidemia (Primatesta and Poulter 2000) are seen to increase. A non-smoking male aged 35–44 with total cholesterol:high-density lipoprotein (HDL) ratio of 6, and a systolic BP of 150 mmHg, has a 15% risk of a coronary event over the next 10 years. At 45–64, bearing the same systolic BP and cholesterol levels (though in reality both may increase with age), his risk is between 15% and 30%. At 65 years, his risk is greater than 30%. Interestingly,

the impact of the modifiable risk factors diminishes with age, for example, an analysis of 10 cohort studies found that lowering total cholesterol by 10% was associated with a 54% CHD risk reduction in men aged 40 years, but only a 20% reduction in men aged 70 years (Figure 3) (Law et al 1994). Taken together, these examples support the concept that risk factor management should be implemented early and aggressively to be most effective.

Epidemiological studies have demonstrated a continuum of risk for increasing levels of BP, total cholesterol (TC), low-density lipoprotein (LDL), and smoking (Wilson et al 1998). For BP beginning at 115/75 mmHg, the risk of CVD doubles with each increment of 20/10 mmHg (Chobanian et al 2003). Similarly, the risk of CHD and CVD increases in a similar manner with LDL cholesterol (LDL-C) concentration (Neaton and Wentworth 1992; Stamler et al 1993; Thomas et al 2002). This has important implications for disease management. In an environment where some international guidelines still outline therapeutic cut-off points for BP and LDL-C, it is critical for physicians (and indeed patients) to understand that there is no threshold where CV risk ceases to exist. There is no level of risk that can be considered “safe”. In response to these findings, target levels for LDL-C and BP have moved progressively downwards. This trend is set to continue as a number of studies have provided evidence that intensive lipid-lowering therapy that reduces LDL-C beyond the levels currently recommended is associated with reduced progression of coronary atherosclerosis and greater protection against death or major CV events than more moderate therapy (Cannon et al 2004; Nissen et al 2004a).



^aBhatt et al 2006
HTN, hypertension; REACH, The Reduction of Atherothrombosis for Continued Health. Risk factors include: treated diabetes mellitus, diabetic nephropathy, asymptomatic carotid stenosis $\geq 70\%$, systolic blood pressure ≥ 150 mm Hg, treated hypercholesterolemia, current smoking, men ≥ 55 years, women ≥ 70 years.

Figure 2 Most hypertensive patients have additional risk factors (Bhatt et al 2006).




Figure 3 Influence of age on relationship between cholesterol and coronary heart disease (CHD) (Law et al 1994).

Another important finding is that the increased risk of CVD resulting from multiple risk factors is frequently greater than simply additive (Neaton and Wentworth 1992; Thomas et al 2002). Using data from the Multiple Risk Factor Intervention Trial (MRFIT), Neaton and colleagues examined the interaction between TC levels, systolic BP, smoking, and CHD death rates (Neaton and Wentworth 1992). Figure 4 illustrates the strong, graded relationship between increasing TC levels and CHD death across systolic BP levels, and the similarly strong relationship between increasing systolic BP and CHD death across TC levels. When risk factors were analyzed together, patients in both the highest TC and the highest systolic BP quintiles had an approximately 11-fold greater risk of CHD death than patients who were in both the lowest TC and lowest systolic BP quintiles (Neaton and Wentworth 1992). Similarly, Liao et al studied a cohort of more than 15,800 Americans and found that the incidence rate of CVD events observed in patients with hypertension

and elevated LDL-C was 51 per 10,000 person years (Liao et al 2004). This was significantly larger than the sum of the incidence rates expected due to either condition alone (28 per 10,000 person years). The excess risk of 31% indicates synergism between these two risk factors. Pathophysiology studies have provided potential mechanisms by which hypertension and dyslipidemia might synergistically accelerate atherosclerosis, including increased endothelial permeability (Meyer et al 1996), increased intimal retention of atherogenic lipoproteins (Rakugi et al 1996), exacerbation of inflammation (Barter 2005; Bautista et al 2005), and increased free radical production (Rodriguez-Porcel et al 2003); all of which may contribute to endothelial dysfunction (Bonetti et al 2003).

The significance of the relationships between CV risk factors and CVD events have been elegantly demonstrated in the results of recent clinical trials and meta-analyses which have assessed the effects of intensive interventions




Figure 4 The additive effect of cholesterol and systolic blood pressure on the risk of coronary heart disease death. Reproduced with permission from Neaton JD, Wentworth D. 1992. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. *Arch Intern Med*, 152:56–64. Copyright © 1992. American Medical Association. All rights reserved.

aimed at reducing modifiable risk factors for CVD (Gaede et al 2003; Julius et al 2004; Baigent et al 2005). Based on a meta-analysis of clinical trials enrolling 90,056 patients Baigent et al concluded that, regardless of baseline LDL-C levels, the 5-year risk of major coronary events, coronary revascularization, and stroke was lowered by approximately 20% per 1 mmol/L (38.8 mg/dL) reduction in LDL-C (Baigent et al 2005). Similarly, Turnbull et al demonstrated in a meta-analysis of randomized trials of antihypertensives that the relative risks of stroke and major CV events were significantly reduced (by 28% and 22%, respectively) when systolic BP was lowered by an average of 5 mmHg using angiotensin-converting enzyme (ACE) inhibitor-based regimens versus placebo (Turnbull 2003). The Steno-2 study demonstrated that in patients with type 2 diabetes and microalbuminuria, intensive interventions targeted at hyperglycemia, hypertension, dyslipidemia, and microalbuminuria, together with the secondary prevention of CVD using aspirin, could reduce the risk of CVD by 50% versus conventional treatment (Gaede et al 2003).

The way in which the multiple risk factors for CVD cluster dictates that the disease should be approached in a way that takes all of these risk factors into account when evaluating risk and when choosing the most appropriate treatment. Addressing only a single risk factor will reduce an individual's CVD risk but leave a substantial residual risk; such a strategy equates to "missing" those patients who are at long-term risk of disease and leads to chronic sub-optimal management of the disease. In contrast, a population-wide intervention to reduce both systolic BP and TC could reduce CVD events by 45% (Emberson et al 2004).

Key points

- Risk factors for CVD frequently cluster in individuals and can act in a synergistic manner to increase the risk of CV events.
- Age is an important unmodifiable risk factor for CVD. With increasing age, the 10-year risk of CVD increases steeply.
- There is a continuum of risk for CVD with increasing levels of BP, TC, LDL-C, and smoking; and this risk is greater still in individuals with diabetes. There is no lower threshold level at which CVD risk ceases to exist.

Current approach to managing these factors

There are numerous guidelines for the treatment and management of individual risk factors such as hypertension

(Chobanian et al 2003; Mancina et al 2007) and dyslipidemia (National Cholesterol Education Program 2001), as well as joint guidelines for the prevention of atherosclerosis and CVD (De Backer et al 2003; Joint British Societies 2005). The mutual underlying principles of these guidelines include the following:

- CV risk assessment.
- Treatment of those at high risk for disease.
- Management adjusted to patient's total risk of CHD or CVD; the higher the risk, the greater the intensity of management.
- Employment of a range of interventions to address risk factors for CVD, including treatment of hypertension, treatment of dyslipidemia, smoking cessation, increased physical activity, cardioprotective diet, treatment of hyperglycemia, weight management, antiplatelet/anticoagulant therapy, and psychosocial support.

Considering the body of scientific evidence that supports these guidelines, the management of CVD should include all of these elements, as a minimum. However, the success (in terms of lowering CV risk) in disseminating relevant new clinical data and implementing treatment guidelines has in general been disappointing (Erhardt et al 2004). Surveys and observational studies continue to demonstrate that the management/control of CV risk factors is poor – even in developed countries where more resources exist for implementing guidelines (EUROASPIRE I and II Group 2001; Johnson et al 2006; Wong et al 2006). The REACT survey, conducted with physicians from 5 European countries, showed that while 81% of practitioners agreed with therapeutic guidelines and reported using them, only 18% felt that the guidelines were being implemented to any great extent (Hobbs and Erhardt 2002). There are various issues that prevent guidelines from being implemented effectively and thus inhibit the successful reduction of CV risk (Table 2). A discussion paper regarding implementation of guidelines for CVD is provided by Erhardt et al (Erhardt et al 2004).

In recent years, the most relevant development in CVD guidelines has been the acknowledgement of the multifactorial nature of CVD. Too often, the treatment focus will be on a single risk factor that might lower the risk by up to 20%–30%, however, it must be remembered that the residual risk in this individual is still 70%–80%; more can be done. This has resulted in a positive shift from management based solely on single risk factors, towards managing a patient's total CV risk, as demonstrated by the incorporation of tools for calculating CV risk into recent treatment guidelines (National Cholesterol Education Program 2001; De Backer et al 2003;

Table 2 Factors that influence the implementation of CVD guidelines

Barrier to implementation	Examples
System-related	Limited reimbursement Increased liability Inadequate staffing resource Lack of specialist support Lack of counseling materials
Physician-related	Inadequate identification of individuals at risk for CVD (De Muylder et al 2004; Hobbs and Erhardt 2002) Inadequate counseling of patients regarding the severity of the disease and the need for adequate adherence to prescribed medications (Egede 2003) Failure to increase treatment intensity (Simpson et al 2003) Lack of critical evaluation of guidelines (Faergeman 1999) Aversion to polypharmacy Confusion/lack of belief in contradictory guidelines Inertia to changing medical practice Budgetary concerns
Patient-related	Poor understanding/awareness of personal disease risk (Cabana et al 1999) Poor long-term adherence with lifestyle changes and poor adherence with CV-risk reducing medications (Chapman et al 2005; Avorn et al 1998)

Abbreviation: CVD, cardiovascular disease.

Joint British Societies 2005). However, the understanding of the importance of this approach has still not had far-reaching impact and has not been implemented in a uniform manner, as highlighted by the management conundrums outlined below, some of which have their foundations entrenched in the fact that CVD is a multifactorial disease.

Management conundrums

As management guidelines evolve, based on emerging clinical data, they will invariably include elements of scientific evidence, practicality, consensus, and compromise. There will always be the inevitable challenge of bridging the gap between theory and practice. Today, there are a number of conundrums regarding the management of CVD which continue to be debated and have yet to be effectively addressed within current guidelines.

Population versus high-risk approach?

Two approaches to primary prevention are generally recognized: the high-risk approach which involves the identification and treatment of only those individuals at high risk; and the population approach which involves population-wide changes in risk factors so that the entire population distribution of those with CVD is shifted, meaning that less individuals fall within the “at risk” level (Figure 5). The high-risk approach is the most obvious choice for those concerned about the CV risk of the individual patient, limiting treatment to only those most likely to have a CV event

in the short term. However, this is complicated by the fact that on a population basis, most CV events do not occur in the small number of high-risk individuals but rather in the much larger proportion of patients in the low-to-moderate risk stratum. For example, MacMahon and Rodgers found that 75% of strokes occur among those with “normal” BP levels (MacMahon and Rodgers 1994).

Consequently, if the primary focus of management is on treating the minority of individuals at high risk, while the individual patient may benefit, the impact on national mortality and morbidity figures will remain almost unchanged because intervention is only provided to a small number of individuals. To achieve a considerable impact on CVD requires an approach that serves the individual with overt disease as well as those with risk factors that predispose them to disease in later life. Long-term pharmaceutical drug use can only be justified in a limited number of people. Therefore, a strategy that reduces the level of risk in the entire population is required. Hence a combination of high-risk and population approaches is needed. A number of advantages and disadvantages of these two approaches are outlined in Table 3.

Who should be considered as high risk?

We have already determined that because of the continuum of risk, there is no level of CVD risk which can be considered as “safe”. In addition, advancing age confers an increasing risk for CVD to the patient, so the individual’s 10-year risk is continually changing. Guidelines differ with




Figure 5 Pictorial representation of the distribution of risk for cardiovascular disease, and high-risk and population-based management strategies.

respect to the definition of high risk, depending on health system and health policy environments. Many currently used guidelines define patients at high risk as those with a 30% absolute risk of developing a CV event within the next 10 years. More recent guidelines have changed the definition of high risk to encompass patients with $\geq 20\%$ risk of CV events (Joint British Societies 2005). The reason why these levels are chosen is based on a number of factors including scientific, financial, practical, as well as political issues. However, as we have also shown, the number of patients that fall within this 20%–30% of risk is small. Adoption of 20%–30% 10-year risk as an indication for therapy denies a huge proportion of individuals the opportunity to prevent or delay a first vascular event, and subjects the individual to years of potential atherogenic damage.

Emberson et al elegantly demonstrated that with high-risk strategies, the higher the level at which high risk is defined, the less effective the reduction in CVD levels is (Figure 6) (Emberson et al 2004). Furthermore, they found

that aggressive treatment in individuals with a 10-year Framingham risk of $\geq 30\%$ would theoretically reduce the occurrence of major CVD by approximately 11%, this increased to 34% when a $\geq 20\%$ high-risk threshold was employed. However, when modest (10%) downshifts to the population distribution of serum TC and systolic BP were applied, a reduction in major CVD by 45% was observed (Emberson et al 2004).

This leads to the question of whether the definition of “high risk” used as an indicator for therapeutic intervention in guidelines is set too high. The answer is probably “yes”. Considering that CV risk factors may start to cluster early in life (Bao et al 1994), it is essential that the risk factor burden of people in their second and third decades is reduced. Essentially, a shift is needed in the perception of those who are at risk. Many guidelines still focus on absolute 5-, 7-, or 10-year projections of CHD or CVD risk (National Cholesterol Education Program 2001; De Backer et al 2003; Joint British Societies 2005). This may be an inadequate approach in younger or

Table 3 Advantages and disadvantages of high-risk and population approaches to CVD management

	Advantages	Disadvantages
Individualized high risk approach	Easy to motivate the patient Provides high risk: benefit ratio	Limited potential for impact Weak predictive power More CVD cases among the large numbers at low-medium risk
Population approach	Radical Large potential benefit for impact by reducing the number of those at risk	Small benefit to the individual Difficult to motivate the patient Risk: benefit ratio unknown

Abbreviations: CVD, cardiovascular disease.




Figure 6 The impact of different levels of Framingham-predicted 10-year risk of cardiovascular disease (CVD) on the percentage reduction of CVD and the proportion of patients treated. Reproduced with permission from Emberson J, Whincup P, Morris RW, et al 2004. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. *Eur Heart J*, 25:484–91. Copyright © Oxford University Press.

middle-aged patients. For example, a 50-year-old man with high cholesterol and hypertension has a 10-year risk of heart attack or coronary death of only 7%, but a lifetime risk that is 10-times greater (Lloyd-Jones et al 2006).

Ideally, what is needed is a longer – preferably lifetime – risk assessment in order that interventions can be applied in time to prevent underlying vascular events. However, the level finally chosen to delineate high risk will ultimately be a decision based on cost, ie, what level of risk can affordably be managed on a large scale. Hence, while scientific knowledge will continue to promote reducing the level that constitutes high risk, lack of funding and political arguments will continue to promote maintaining the level at that which is affordable.

Relative or absolute risk?

Knowledge of the multifactorial nature of CVD has prompted the development of management systems based on “absolute risk” of developing CVD. Absolute risk – the actual odds that a patient (or population) will develop an event over a given period of time – reflects the sum of all the factors that contribute to the risk of CVD. Absolute risk always increases with advancing age, irrespective of the level of BP, cholesterol, or of smoking habits. This measurement is useful in that it allows identification of individuals who need to be advised immediately about risk factor reduction. However “relative risk” measurements can also be a useful tool for clinicians, particularly in younger patients with a low absolute risk, because they can provide information regarding who is at

a high relative risk compared with their peers and who may benefit from aggressive risk factor reduction in the long term. The recently updated ESH-ESC guidelines recommend that treatment of younger patients should be based on their relative risk rather than their absolute risk (Mancia et al 2007). These updated preventive guidelines also contain relative risk scores for younger individuals to facilitate the understanding of risk in these individuals who have a low absolute 10-year risk of CVD events.

Conversely, when formulating public health policy absolute risk reductions should be used as these provide a far more meaningful measure of what can be achieved at the population level. For example, reducing the daily salt intake from 9.5 g to 6 g will lead to a 13% reduction in stroke and a 10% reduction in heart disease (Medical Research Council 2006).

Cardiovascular risk calculators are available that measure either absolute or relative risk, so it will be interesting to observe whether the useful information that can be derived from both of these measurements will be used to its fullest in the future.

Key points

- CVD guidelines have evolved to take account of the multifactorial nature of CVD, resulting in management strategies centered on lowering a patient’s total CV risk.
- Implementation of CVD guidelines is poor.
- To achieve a considerable impact on CVD requires a management approach that serves the individual with risk factors that predispose them to disease in later life as well as those with overt disease.

Recommended optimal approach

Based on the issues discussed above, the following represents our attempt at outlining what the optimal approach to CVD management might involve. While we accept that practicalities may always lie in the way of achieving what is essentially an idealistic approach, an appreciation of appropriate goals is an important step in improving management practices.

Step 1: Identifying patients at risk/ estimating level of total lifetime risk

Recognizing patients who are at risk of a CV event is the first step to achieving effective prevention. Patients with existing CVD are usually at high risk for recurrent CVD events, but healthy patients with multiple CV risk factors may be as likely to suffer a CVD event as those with clinically manifest disease. It is a particularly important step for those with existing CV risk factors, as other CV risk factors likely coexist. When one CV risk factor has been identified, especially hypertension, regular screening for other CV risk factors is desirable.

Indeed, it can be argued that the concepts of primary and secondary prevention are now obsolete (Plummer 2006). Firstly, as mentioned above, apparently healthy individuals with no previous CV events, may have asymptomatic indications of CVD, such as carotid artery stenosis and left ventricular hypertrophy, and thus may be at higher risk than those who have had CV events. Secondly, a patient may be unaware that they have had a CV event and thus if treatment recommendations are based on the occurrence of a CV event rather than their risk of a future event such patients would be managed inappropriately. For example, approximately 20% of MIs were unrecognized in the Atherosclerosis Risk in Communities (ARIC) study (Boland et al 2002).

Considering the many variables that need to be considered in calculating an individual's risk for CVD, it is essential that a properly validated risk assessment tool be used to help the physician derive an accurate picture of the individual's risk. Effective risk assessment tools estimating absolute CV risk are available and should be used to identify people at high risk for CVD. They should be considered an aid to making clinical decisions about how intensively to intervene on lifestyle and how to proceed with the use of antihypertensive, lipid-lowering, and other modifiable risk factor medications. There are many variables that confer risk which are not included in the common risk algorithms – dietary and exercise habits, and psychosocial factors – and therefore any risk assessment must be individualized and include these factors. Furthermore, a positive family history and diabetes mellitus, not included in

most risk algorithms, increases the risk of CVD significantly. Consequently, risk assessment tools are never exact and should be used *in combination with* clinical judgment.

In recent years web-based systems, score card methods, and tools such as the “Grimm Meter” have become available and have simplified the risk assessment procedure (Thomsen et al 2001; Conroy et al 2003; Gohlke et al 2005; Grimm and Svendsen 2006). Many risk assessment tools are available that are of benefit in particular patient populations. A detailed review of these methods is outside the scope of this review (see Grover et al 2006 for a recent review).

The decision over which risk assessment tool to employ is somewhat less important than the choice to actually use a risk assessment tool. As most tools generally arrive at a similar *estimation* of risk, the actual tool chosen is probably not critical. However, it is essential that some form of risk assessment is used as this leads to improved estimation of patient risk and hence better management. A study by Backlund et al demonstrated that physicians often underestimate their patients CV risk (Figure 7) (Backlund et al 2004), and other studies show that physicians rarely or never use tools when calculating a patient's CVD risk (Hobbs and Erhardt 2002; De Muyllder et al 2004). Hobbs and Erhardt showed that 43% of physicians reported that they never use risk calculator charts that may accompany guidelines, a further 43% said they sometimes referred to them, but only 13% said that this was always the case (Hobbs and Erhardt 2002).

There are some important caveats to using risk assessment tools. First, it is important for clinicians to appreciate that such tools provide only an *estimate* of risk. Biologic variability might mean that someone with a very low risk score could experience a CV event and someone with a very high chance of experiencing an event may not. Second, the outcome of the risk scoring exercise may not be the only reason why a physician may choose to offer an intervention; clinical judgment and thorough individual assessment (including exercise habits, food habits, and psychosocial factors) also need to play a role. Third, risk evaluation alone does not provide adequate information to help the patient understand their own risk and begin to make steps towards improving their own modifiable risk factor status. There are many physician- and patient-related barriers to communications regarding risk, an understanding of which is important for fully utilizing information arising from risk evaluation measures. Fourth, without improving therapeutic intervention, risk scoring is of little use. As Zimmerman and Horton-La Forge noted in 1996, “little evidence exists to suggest that risk assessment alone, without more intensive intervention, can have a lasting




Figure 7 Physicians underestimation of their patients' cardiovascular risk (Backlund et al 2004)

impact on health behaviors or health risks" (Zimmerman and Horton-La Forge 1996).

Step 2: Helping the patient to understand their personal risk

Providing patients with their CVD risk score is a useful means of motivating patients towards healthy behaviors (Sullivan et al 2004; Alm-Roijer et al 2006). An understanding of both the fatal consequences and also the potential debilitating effects of nonfatal CV events, such as MI or stroke, may encourage patients to adhere to CV medications and life-style changes. However, this may be a little simplistic because uninformed patients may have difficulty in understanding the concepts of risk (Knapp et al 2004). Knapp et al found that the use of verbal descriptors to improve the level of information about side-effect risk leads to overestimation of the level of harm and may lead patients to make inappropriate decisions about whether or not they take the medicine (Knapp et al 2004). It is difficult, then, for the physician to decide what information to provide about CV risk. As a guide, physicians might wish to consider the following areas for communication with their patients:

Probability: Focus on the *relative* risk faced by that particular patient. Patients with CHD benefit from having specific individualized knowledge about their condition and their own risk factor status for promoting adherence to lifestyle changes and medical treatment (Alm-Roijer et al 2006);

Exposure: Communicate that *everyone* faces the risk of CVD;

Hazard: Emphasize the modifiable *risk factors* the patient can control;

Consequences: Create a *mental picture* of CVD events, without creating fear, because this can influence whether

a patient takes prescribed medications (Knapp et al 2004). Within this concept, it is important to reiterate the need for adherence to both lifestyle changes and medications. Previous studies have clearly demonstrated that the percentage of patients who are adherent to both antihypertensive and lipid-lowering therapies declines sharply within the first year of therapy initiation (Chapman et al 2005). Furthermore, a link between low adherence to CV medications and poor clinical outcome has been demonstrated in a variety of settings (Wei et al 2002; Ho et al 2006a, b).

Considering the challenges associated with establishing and maintaining effective communication with the CVD patient, and the consequences faced when this is not effectively achieved, it is likely that utilizing other healthcare professionals in the provision of in-depth counseling could be an advantage. With this in mind, the Risk Evaluation and Communication Health Outcomes and Utilization Trial (REACH OUT) has recently been completed. The study will assess the ability of a physician-delivered CHD risk evaluation and communication program to lower a patient's predicted 10-year risk of MI or death due to CHD by 10% within 6 months, compared with usual care. Results from this trial are anticipated towards the later part of 2007. The results of this study promise to be of great interest to all of those involved in managing patients with CVD.

Step 3: Developing a comprehensive management strategy for the individual patient

An effective management strategy for CVD should contain some element of lifestyle modification as well as pharmaceutical intervention, where appropriate (Figure 8). As a first




Figure 8 Comprehensive management strategy for patients with cardiovascular disease risk factors.

step in the management of their overall CVD risk, patients should be encouraged to adhere to healthy lifestyle habits. Patients should be informed of the benefits of smoking cessation, exercise, diet modification, and weight loss. A recent study supports this concept and has indicated that as many as 62% of CV events in men are preventable through adopting a low-risk lifestyle (Chiuve et al 2006). Compared with men who did not make lifestyle changes during follow-up in this study, those who adopted ≥ 2 additional low-risk lifestyle factors had a 27% lower risk of CHD (Chiuve et al 2006).

Where lifestyle changes are insufficient, therapy is advised. This should include a range of interventions such as treatment of hypertension, dyslipidemia, hyperglycemia, and antiplatelet/anticoagulant therapy.

It is important that the physician and patient closely collaborate to develop a management strategy that will suit the individual patient. One study showed that a multidimensional integrative approach, which identified specific health behaviors important for each patient to modify, was able to significantly reduce the risk of CVD. The patient, together with a health coach and a medical provider, devised a personal health plan which was driven not only by CV risk reduction but also the interests of the patient. Techniques used to help implement

the health plan included meditation, relaxation training, stress management, motivational techniques, and health education and coaching (Edelman et al 2006). It has been suggested that by working together, a goal-setting effort between patient and physician/medical team – if employed and adhered to – can help reduce CV risk (MacGregor et al 2006).

Given the multifactorial nature of CVD it is not surprising that clinical trials have consistently demonstrated that multiple CV risk factors should be managed simultaneously to maximize reductions in CV events (Samuelsson et al 1987; Sever et al 2003). The downside to this approach is that increasing pill burden and prescription costs can decrease adherence to treatment (Chapman et al 2005; Safran et al 2005; Lynch 2006; Soumerai et al 2006). Consequently, the development of multi-modal drugs, which in a single pill can target a number of risk factors, is a promising approach. In 2003, Wald and Law introduced the concept of combining medicines for effective risk factor reduction by use of the Polypill™. They proposed that a single, daily pill containing half doses (to minimize toxicity) of a beta-blocker, a thiazide diuretic, an ACE inhibitor, a statin, folic acid, and aspirin, taken by everyone aged >55 could reduce the incidence of CVD by more than 80% (Wald and Law 2003).

Step 4: Providing continued follow-up support

The aims of patient follow-up support should be to assess and communicate to the patient the success of intervention strategies in order to i) maintain patient motivation, ii) identify problems in adherence to the disease management strategy (there is a very real difference between obtaining a prescription for a medication and actually taking it), iii) provide further disease/therapy information.

Follow-up studies have observed that educational programs and counseling on CV risk and events have a significant effect for up to 12 months (Barth et al 2006) and demonstrate the need for continued counseling and follow-up support. However, more information needs to be made available to the physician/medical team to help them provide such follow-up support effectively. Support should also be provided to those who have had a debilitating CV event such as an MI or stroke, who frequently live for many years after such an event.

Key points

- Recognizing patients who are at risk of a CV event is the first step to achieving effective CVD prevention.
- The concepts of primary and secondary prevention are in many ways now obsolete and should be substituted by proper risk calculation and risk stratification.
- Properly validated risk assessment tools should be used to help derive an accurate picture of the patient's total CV risk, but should be used in conjunction with clinical judgment.
- Advising patients of their CVD risk is a useful means of motivating patients towards healthy behaviors, but needs to be done sensitively because the concept of risk can be misunderstood.
- Management for CVD should entail a close collaboration between the physician, other healthcare professionals, and the patient to develop a strategy that will suit the individual patient. It should include elements of lifestyle modification as well as pharmaceutical intervention, where appropriate, to address the multiple CV risk factors likely to be present. Follow-up support should be provided to ensure patient adherence and provide additional support where necessary.

Providing optimal care in a resource-scarce environment

Although the recommended optimal approach discussed above would bring about a substantial reduction in the

prevalence of CVD, we need to be realistic considering the strong financial constraints under which many healthcare systems are operating. Indeed, 80% of the total global burden of CVD is carried by countries of low/moderate income (WHO 2005). Disease prevention with statins and antihypertensive therapy has been shown to be cost-effective as the morbidity and mortality reductions and increases in life expectancy can be considerable (McMurray 1999; Pilote et al 2005). Nonetheless, further research is needed to acquire knowledge of the long-term cost consequences of various treatments and interventions. Cost-effective interventions to reduce the burden of CVD can only be implemented if health services policy environments and financial resources allow. For many (if not most) countries, the individual management of large numbers of patients, outside the high-risk sphere for CVD, will simply not be affordable. So what can be done to maximize any management efforts that are made in such countries?

Other healthcare providers

Implementation of a medical team approach in dealing with the patient's needs is likely to be a more effective strategy than heavy reliance on the physician. Nurse-led care-share programs have been shown to be successful in providing the additional support and health promotion needed for effective management of CVD. Also, nurse evaluation of CV risk and medication adherence prior to and/or following the physician visit may help reinforce messages surrounding the importance of the illness and the need to adhere to prescribed therapies and lifestyle changes; and often patients find it easier to discuss such issues with a nurse. One UK study compared intensive management by nurses with routine follow-up in general practice for patients with CHD. Patients who received intensive nurse-led care reported improvements in their health, functional status, and in the likelihood of hospitalization within the first year of care (Campbell et al 1998). In the USA, nurse case managers help in the care of patients in the out-patient setting. Their role includes securing long-term patient adherence and follow-up; developing clinic policy and computerized patient databases, and implementing management according to established CHD guidelines (Thomas et al 1997).

Care programs such as those described above are likely to be critical in improving care within any environment, but particularly those with limited resources. The most effective way of optimizing the outlay spent on managing CVD is to ensure that treatment applied is appropriate, that the patient adheres to the treatment and that, ultimately, risk factors for the disease are controlled.

Key points

- Providing optimal care for CVD is challenging considering the strong financial constraints under which many healthcare systems are operating.
- The most effective way of optimizing the outlay spent on managing CVD is to ensure that the treatment applied is appropriate, that the patient adheres to the prescribed treatment and that, ultimately, risk factors for CVD are controlled.
- The implementation of an effective nurse-patient interaction may improve the CV management.

What can we hope for in the future?

Guidelines relevant to CVD continue to evolve and improve. Significant advances were made in recent Canadian guidelines, on a number of levels, ie, by including global estimates of patient's risk, by providing guidance on improving patient treatment adherence, and by improving the way in which the guidelines are disseminated and implemented (Drouin et al 2006; Khan et al 2006). The Canadian Hypertension Education Program (CHEP) recognizes that annually-updated, evidence-based guidelines for hypertension alone are not sufficient to improve the management of hypertension in Canada and have thus included an Implementation Task Force whose role it is to enhance dissemination and implementation of hypertension guidelines. Considering the impact that CHEP may have had on improvements in the management of hypertension in Canada, it is possible that it may serve as a model for disease management recommendations (Drouin et al 2006).

The recently updated ESH-ESC guidelines (Mancia et al 2007) will also help to reinforce key messages; the guidelines emphasize the importance of assessing total CV risk, implementation of life-style changes, and blood pressure reduction *per se* rather than the antihypertensive class selected. In addition, the new guidelines recommend that combination therapy should be considered from the start (the choice of drug should be based on patient comorbidities), the threshold for initiating treatment should be more flexible ($>140/90$ mm Hg), and that all high-risk hypertensive patients (those with diabetes, multiple risk factors, or organ damage) should aim for a BP goal of $<130/80$ mm Hg. Moreover, it is noted that absolute risk should be used to guide treatment in the elderly whereas relative risk should be used in younger patients.

In future years, we might also expect to see improvements in risk assessment models and algorithms which measure global lifetime risk for CVD and improve existing models by adding novel risk factors. However, while the search for

novel risk factors continues, any discoveries in this area are likely to be less important than the more thorough implementation of existing risk tools that are based on established risk factors. This is because 80% of CVD risk is conveyed by the 3 major risk factors: smoking, elevated BP, and high serum TC (Emberson et al 2003). With optimal control of these risk factors, significant reduction in CV events may be obtained.

As explained earlier, the concept of a compound that can target multiple risk factors is likely to be an important tool for CVD management. While considerable challenges are likely to be faced in developing a therapy with the optimistic number of components proposed by Wald and Law (2003), inroads are being made with the development of combination therapies for CVD (Blank et al 2005).

Ultimately, preventing an epidemic of CVD will likely require a combination of both medical and public health approaches. Public health strategies that target whole populations may offer a great prospect for reducing CVD.

Key points

- In future years, we might expect guidelines for CVD to evolve further by including elements to further help the patient adhere to prescribed treatment regimens and by including estimates of a patient's global CV risk. Improving the dissemination and implementation of guidelines is likely to be vital in improving the control of CV risk factors.
- Compounds that target multiple risk factors for CVD may improve patient adherence.
- Ultimately, preventing an epidemic of CVD will likely require a combination of both medical and public health approaches.

Conclusion

The management of CVD is currently far from optimal, even in parts of the world with well-developed and well-funded healthcare systems. This is particularly concerning when considering the huge increase in CVD in low-middle income countries where healthcare systems are not funded to manage the growing CV epidemic.

The continued movement away from the treatment of individual CV risk factors to managing overall and lifetime CV risk is likely to have a significant impact on blunting the projected increase in CVD. However, for this to become effective, the importance of this approach needs to be appreciated on an even greater scale and ingrained into every aspect of CVD management.

A broad range of extremely effective lifestyle, counseling, and therapeutic interventions can be used in conjunction with CV risk assessment tools to markedly reduce an individual's risk of CVD. Ultimately, however, quelling the CVD epidemic is likely to require a combination of effectively managing those at high risk of disease, and optimizing widespread population interventions which aim to reduce the number of individuals at risk. Considering the huge consequences of falling short in these aims, the success (or otherwise) in implementing these elements will be scrutinized.

Acknowledgments

Editorial assistance was provided by Jon Edwards of Envision Pharma and funded by Pfizer Inc.

References

- Alm-Roijer C, Fridlund B, Stagmo M, et al. 2006. Knowing your risk factors for coronary heart disease improves adherence to advice on lifestyle changes and medication. *J Cardiovasc Nursing*, 21:E24–E31.
- [AHA] American Heart Association. 2003. International cardiovascular disease statistics. Dallas, Texas: American Heart Association.
- Ansell BJ. 2005. Evidence for a combined approach to the management of hypertension and dyslipidemia. *Am J Hypertens*, 18:1249–57.
- Asmar R, Vol S, Pannier B, et al. 2001. High blood pressure and associated cardiovascular risk factors in France. *J Hypertens*, 19:1727–32.
- Avorn J, Monette J, Lacour A, et al. 1998. Persistence of use of lipid-lowering medications: a cross-national study. *JAMA*, 279:1458–62.
- Backlund L, Bring J, Strender J-E, et al. 2004. How accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients. *Primary Health Care Research and Development*, 5:145–52.
- Baigent C, Keech A, Kearney PM, et al. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet*, 366:1267–78.
- Bao W, Srinivasan SR, Wattigney WA, et al. 1994. Persistence of multiple cardiovascular risk clustering related to syndrome X from childhood to young adulthood. The Bogalusa Heart Study. *Arch Intern Med*, 154:1842–7.
- Barter P. 2005. The inflammation: lipoprotein cycle. *Atheroscler Suppl*, 6:15–20.
- Barth J, Critchley J, Bengel J, et al. 2006. Efficacy of psychosocial interventions for smoking cessation in patients with coronary heart disease: a systematic review and meta-analysis. *Ann Behav Med*, 32:10–20.
- Bautista LE, Vera LM, Arenas IA, et al. 2005. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. *J Hum Hypertens*, 19:149–54.
- Bhatt DL, Steg PG, Ohman EM, et al. 2006. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. *JAMA*, 295:180–9.
- Blank R, LaSalle J, Reeves R, et al. 2005. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (The Amlodipine/Atorvastatin Gemini Study). *J Clin Hypertens*, 7:264–73.
- Boland LL, Folsom AR, Sorlie PD, et al. 2002. Occurrence of unrecognized myocardial infarction in subjects aged 45 to 65 years (the ARIC study). *Am J Cardiol*, 90:927–31.
- Bonetti PO, Lerman LO, Lerman A, et al. 2003. Endothelial dysfunction: a marker of atherosclerotic risk. *Arterioscler Thromb Vasc Biol*, 23:168–75.
- Booth GL, Kapral MK, Fung K, et al. 2006. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. *Lancet*, 368:29–36.
- Cabana MD, Rand CS, Powe NR, et al. 1999. Why don't physicians follow clinical practice guidelines? A framework for improvement. *JAMA*, 282:1458–65.
- Campbell NC, Thain J, Deans HG, et al. 1998. Secondary prevention clinics for coronary heart disease: randomized trial of effect on health. *BMJ*, 316:1434–7.
- Cannon CP, Braunwald MD, McCabe CH, et al. 2004. Intensive and moderate lipid lowering with statins after acute coronary symptoms. *N Engl J Med*, 350:1495–504.
- Chapman RH, Benner JS, Petrilla AA, et al. 2005. Predictors of adherence with antihypertensive and lipid-lowering therapy. *Arch Intern Med*, 165:1147–52.
- Chiuvè SE, McCullough ML, Sacks FM, et al. 2006. Healthy lifestyle factors in the primary prevention of coronary heart disease among men. *Circulation*, 114:160–7.
- Chobanian AV, Bakris GL, Black HR, et al. 2003. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 Report. *JAMA*, 289:2560–72.
- Conroy RM, Pyorala K, Fitzgerald AP, et al. 2003. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J*, 24:987–1003.
- De Backer G, Ambrosioni E, Borch-Johnsen K, et al. 2003. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. *Eur Heart J*, 24:1601–10.
- De Muylder R, Lorant V, Paulus D, et al. 2004. Obstacles to cardiovascular prevention in general practice. *Acta Cardiol*, 59:119–25.
- Drouin D, Campbell NR, Kaczorowski J, et al. 2006. Implementation of recommendations on hypertension: the Canadian Hypertension Education Program. *Can J Cardiol*, 22:595–8.
- Edelman D, Oddone EZ, Liebowitz RS, et al. 2006. A multidimensional integrative medicine intervention to improve cardiovascular risk. *J Gen Intern Med*, 21:728–34.
- Egede LE. 2003. Implementing behavioral counseling interventions in primary care to modify cardiovascular risk in adults with diabetes. *Cardiovasc Rev Rep*, 24:306–12.
- Emberson JR, Whincup PH, Morris RW, et al. 2003. Reassessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. *Eur Heart J*, 24:1719–26.
- Emberson J, Whincup P, Morris RW, et al. 2004. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. *Eur Heart J*, 25:484–91.
- Erhardt LR, Pearson TA, Bruckert E, et al. 2004. Guidelines and their implementation: a discussion document focused on the best approaches to drive improvement. *Vascular Disease Prevention*, 1:1667–74.
- EUROASPIRE I and II Group. 2001. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. *Lancet*, 357:995–1001.
- Faergeman O. 1999. Challenges to best practice: Why are guidelines not implemented. *Eur Heart J Suppl*, 1(Suppl J):J12–J17.
- Felmeden DC, Spencer CG, Blann AD, et al. 2003. Low-density lipoprotein subfractions and cardiovascular risk in hypertension: relationship to endothelial dysfunction and effects of treatment. *Hypertension*, 41:528–33.
- Gaede P, Vedel P, Larsen N, et al. 2003. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med*, 348:383–93.
- Giles TD, Berk BC, Black HR, et al. 2005. Expanding the definition and classification of hypertension. *J Clin Hypertens*, 7:505–12.

- Gohlke HK, Winter M, Karoff M, et al. 2005. CARRISMA: a new tool to optimize cardiovascular risk management in primary prevention [abstract]. *Circulation*, 12:3794 (Abstract).
- Greenland P, Knoll MD, Stamler J, et al. 2003. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. *JAMA*, 290:891–7.
- Grimm R Jr, Svendsen K. 2006. Cardiovascular risk meter: A device for rapid estimation of cardiovascular disease mortality in clinical settings. *J Clin Hypertens*, 8(Suppl A 5) [abstract]:A236 (P-577, MP-55).
- Grover SA, Hemmelgarn B, Joseph L, et al. 2006. The role of global risk assessment in hypertension therapy. *Can J Cardiol*, 22:606–13.
- Haffner SM, Lehto S, Ronnema T, et al. 1998. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med*, 339:229–34.
- Ho PM, Rumsfeld JS, Masoudi FA, et al. 2006a. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. *Arch Intern Med*, 166:1836–41.
- Ho PM, Spertus JA, Masoudi FA, et al. 2006b. Impact of medication therapy discontinuation on mortality after myocardial infarction. *Arch Intern Med*, 166:1842–7.
- Hobbs FD, Erhardt L. 2002. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. *Fam Pract*, 19:596–604.
- Huxley R, Barzi F, Woodward M. 2006. Excess of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. *BMJ*, 332:73–8.
- International Diabetes Federation. Diabetes Atlas, 3rd ed. [online]. URL: <http://www.eatlas.idf.org/media/>
- Jackson R, Lawes CM, Bennett DA, et al. 2005. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. *Lancet*, 365:434–41.
- Johnson ML, Pietz K, Battleman DS, et al. 2006. Therapeutic goal attainment in patients with hypertension and dyslipidemia. *Med Care*, 44:39–46.
- Joint British Societies 2005. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. *Heart*, 91(Suppl 5):v1–v52.
- Julius S, Kjeldsen SE, Weber M, et al. 2004. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet*, 363:2022–31.
- Kannel WB. 2000a. Fifty years of Framingham Study contributions to understanding hypertension. *J Hum Hypertens*, 14:83–90.
- Kannel WB. 2000b. Risk stratification in hypertension: new insights from the Framingham Study. *Am J Hypertens*, 13:3S–10S.
- Khan NA, McAlister FA, Rabkin SW, et al. 2006. The 2006 Canadian hypertension education program recommendations for the management of hypertension: Part II – Therapy. *Can J Cardiol*, 22:583–93.
- Knapp P, Raynor DK, Berry DC, et al. 2004. Comparison of two methods of presenting risk information to patients about the side effects of medicines. *Qual Saf Health Care*, 13:176–80.
- Law MR, Wald NJ, Thompson SG. 1994. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease. *BMJ*, 308:367–72.
- Lerner DJ, Kannel WB. 1986. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. *Am Heart J*, 111:383–90.
- Liao D, Mo J, Duan Y, et al. 2004. The joint effect of hypertension and elevated LDL-cholesterol on CHD is beyond additive. *Eur Heart J*, 25(abstract suppl):235[abstract #1377].
- Lloyd-Jones DM, Leip EP, Larson MG, et al. 2006. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. *Circulation*, 113:791–8.
- Lynch T. 2006. Medication costs as a primary cause of nonadherence in the elderly. *Consult Pharm*, 21:143–6.
- MacGregor K, Handley M, Wong S, et al. 2006. Behavior-change action plans in primary care: a feasibility study of clinicians. *J Am Board Fam Med*, 19:215–23.
- MacMahon S, Rodgers A. 1994. Blood pressure, antihypertensive treatment and stroke risk. *J Hypertens Suppl*, 12:S5–S14.
- McManus B. 2005. INTERHEART: nine factors that could save your life. *Healthc Q*, 8:28.
- McMurray J. 1999. The health economics of the treatment of hyperlipidemia and hypertension. *Am J Hypertens*, 12:99S–104S.
- Mancia G. 2006. Total cardiovascular risk: a new treatment concept. *J Hypertens Suppl*, 24:S17–S24.
- Mancia G, De Backer G, Dominiczak A, et al. 2007. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*, 25:1105–87.
- Medical Research Council. 2006. Why 6g? A summary of the scientific evidence for the salt intake target. Cambridge: Medical Research Council.
- Meyer G, Merval R, Tedgui A, et al. 1996. Effects of pressure-induced stretch and convection on low-density lipoprotein and albumin uptake in the rabbit aortic wall. *Circ Res*, 79:532–40.
- Murray CJ, Lopez AD 1997. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. *Lancet*, 349:1498–504.
- Natarajan S, Liao Y, Cao G, et al. 2003. Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. *Arch Intern Med*, 163:1735–40.
- National Cholesterol Education Program. 2001. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA*, 285:2486–97.
- Neaton JD, Wentworth D. 1992. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. *Arch Intern Med*, 152:56–64.
- Nissen SE, Tuzcu EM, Schoenhagen P, et al. 2004. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. *JAMA*, 291:1071–80.
- O'Meara JG, Kardia SL, Armon JJ, et al. 2004. Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. *Arch Intern Med*, 164:1313–18.
- Pilote L, Ho V, Lavoie F, et al. 2005. Cost-effectiveness of lipid-lowering treatment according to lipid level. *Can J Cardiol*, 21:681–7.
- Plummer CJ. 2006. What's in the CARDS. *Diab Med*, 23:711–14.
- Primates P, Poulter NR. 2000. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. *BMJ*, 321:1322–5.
- Puska P, ed. 1988. Comprehensive cardiovascular community control programmes in Europe. Copenhagen: WHO Regional Office for Europe (EURO Reports and Studies 106).
- Puska P, Vartiainen E, Tuomilehto J, et al. 1998. Changes in premature deaths in Finland: successful long-term prevention of cardiovascular diseases. *Bull World Health Organ*, 76:419–25.
- Rakugi H, Yu H, Kamitani A, et al. 1996. Links between hypertension and myocardial infarction. *Am Heart J*, 132:213–21.
- Rayner M. 2000. European Cardiovascular Disease Statistics.
- Reaven GM, Lithell H, Landsberg L, et al. 1996. Hypertension and associated metabolic abnormalities – the role of insulin resistance and the sympathoadrenal system. *N Engl J Med*, 334:374–81.
- Rodriguez-Portel M, Lerman LO, Herrmann J, et al. 2003. Hypercholesterolemia and hypertension have synergistic deleterious effects on coronary endothelial function. *Arterioscler Thromb Vasc Biol*, 23:885–91.
- Rosamond W, Flegal K, Friday G, et al. 2007. Heart disease and stroke statistics–2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*, 115:e69–e171.

- Safran G, Neuman P, Schoen C, et al. 2005. Prescription drug coverage and seniors: findings from a 2003 national survey. *Health Aff*, Jan–Jun; Suppl Web Exclusives:W5-152–W5-166.
- Samuelsson O, Wilhelmsen L, Andersson OK, et al. 1987. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the primary prevention trial in Goteborg, Sweden. *JAMA*, 258:1768–76.
- Sever PS, Dahlöf B, Poulter NR, et al. 2003. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet*, 361:1149–58.
- Simpson E, Beck C, Richard H, et al. 2003. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. *Am Heart J*, 145:438–44.
- Soumerai SB, Pierre-Jacques M, Zhang F, et al. 2006. Cost-related medication nonadherence among elderly and disabled Medicare beneficiaries: a national survey 1 year before the medicare drug benefit. *Arch Intern Med*, 166:1829–35.
- Stamler J, Vaccaro O, Neaton JD, et al. 1993. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care*, 16:434–44.
- Sullivan LM, Massaro JM, D'Agostino RB, Sr, et al. 2004. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. *Stat Med*, 23:1631–60.
- Thomas F, Bean K, Guize L, et al. 2002. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. *Eur Heart J*, 23:528–35.
- Thomas TS. 1997. Improving care with nurse case managers: practical aspects of designing lipid clinics. *Am J Cardiol*, 80:62H–65H.
- Thomsen TF, Davidsen M, Ibsen H, et al. 2001. A new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials; PRECARD and the Copenhagen Risk Score. *J Cardiovasc Risk*, 8:291–7.
- Turnbull F. 2003. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet*, 362:1527–35.
- Vartiainen E, Puska P, Pekkanen J, et al. 1994. Changes in risk factor explain changes in mortality from ischaemic heart disease in Finland. *BMJ*, 309:23–7.
- Vasan RS, Beiser A, Seshadri S, et al. 2002. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. *JAMA*, 287:1003–10.
- Wald NJ, Law MR. 2003. A strategy to reduce cardiovascular disease by more than 80%. *BMJ*, 326:1419.
- Wei L, Wang J, Thompson P, et al. 2002. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. *Heart*, 88:229–33.
- Wild S, Roglic G, Green A, et al. 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care*, 27:1047–53.
- Wilson PW, D'Agostino RB, Levy D, et al. 1998. Prediction of coronary heart disease using risk factor categories. *Circulation*, 97:1837–47.
- Wong ND, Lopez V, Tang S, et al. 2006. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. *Am J Cardiol*, 98:204–8.
- [WHO] World Health Organization. 2005. Cardiovascular disease: prevention and control. Geneva: World Health Organization.
- Yoon KH, Lee JH, Kim JW, et al. 2006. Epidemic obesity and type 2 diabetes in Asia. *Lancet*, 368:1681–8.
- Yusuf S, Hawken S, Ounpuu S, et al. 2004. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet*, 364:937–52.
- Zimmerman EM, Horton-La Forge B. 1996. Detection and prevention of cardiac risk factors: health risk assessment and targeted follow-up in a managed care population. *J Cardiovasc Nurs*, 11:27–38.

